Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) was the target of a large drop in short interest in August. As of August 15th, there was short interest totalling 47,200 shares, a drop of 5.0% from the July 31st total of 49,700 shares. Based on an average trading volume of 45,300 shares, the short-interest ratio is currently 1.0 days. Currently, 3.6% of the shares of the stock are short sold.
Avenue Therapeutics Trading Up 0.7 %
NASDAQ ATXI opened at $2.81 on Thursday. The firm has a market capitalization of $2.64 million, a price-to-earnings ratio of -0.36 and a beta of -0.17. The firm’s 50 day simple moving average is $2.98 and its 200 day simple moving average is $6.07. Avenue Therapeutics has a 1 year low of $2.25 and a 1 year high of $64.27.
Avenue Therapeutics (NASDAQ:ATXI – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).
Institutional Investors Weigh In On Avenue Therapeutics
Avenue Therapeutics Company Profile
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Featured Articles
- Five stocks we like better than Avenue Therapeutics
- Insider Buying Explained: What Investors Need to Know
- Why Dick’s Could Be a Slam Dunk for Your Investment Portfolio
- Options Trading – Understanding Strike Price
- Introduction to Fibonacci Retracement Levels
- EV Stocks and How to Profit from Them
- Top 3 Stocks to Outperform the S&P 500 in a Downturn
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.